Brief: Matinas Biopharma Reports Q4 Loss Per Share Of $0.04

Matinas BioPharma Holdings

09/03/2020 11:11

March 9 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR
2019
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
    * Q4 LOSS PER SHARE $0.04
    * Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES
DATA
    * INITIATED ENHANCE-IT STUDY OF MAT9001 AGAINST VASCEPA.
TOPLINE
DATA EXPECTED Q4 2020
    * INITIATED EFFICACY PHASE OF NIH-FUNDED ENACT STUDY OF
MAT2203 IN
CRYPTOCOCCAL MENINGITIS Q1 2020
    * MATINAS BIOPHARMA HOLDINGS - BASED ON CURRENT PROJECTIONS,
CO
BELIEVES THAT CASH ON HAND IS SUFFICIENT TO FUND OPERATIONS INTO
SECOND HALF OF 2022
    * MATINAS BIOPHARMA - PLANS TO ANNOUNCE PROGRESSION FROM
COHORT TO
COHORT OVER COURSE OF 2020, BUT FULL DATA FROM MAT2203 ENACT
WILL NOT BE AVAILABLE UNTIL SECOND HALF 2021

Source text for Eikon:  ID:nGNX1VcyBQ 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))